ANI Pharmaceuticals - ANIP Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANIP shares.
View ANIP analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 12 month price objectives for ANI Pharmaceuticals' shares. Their ANIP share price forecasts range from $48.00 to $70.00. On average, they predict the company's share price to reach $56.00 in the next year. This suggests a possible upside of 74.2% from the stock's current price.
View analysts price targets for ANIP or view top-rated stocks among Wall Street analysts.

ANI Pharmaceuticals' stock was trading at $46.08 at the beginning of 2022. Since then, ANIP stock has decreased by 30.3% and is now trading at $32.14.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 7th 2022.
View our ANIP earnings forecast.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) issued its earnings results on Monday, August, 8th. The specialty pharmaceutical company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.01. The specialty pharmaceutical company earned $73.86 million during the quarter, compared to analysts' expectations of $71 million. ANI Pharmaceuticals had a positive trailing twelve-month return on equity of 3.68% and a negative net margin of 25.32%. During the same quarter in the prior year, the firm posted $0.49 EPS.

ANI Pharmaceuticals updated its FY 2022 earnings guidance on Tuesday, September, 6th. The company provided EPS guidance of $1.34-$1.62 for the period, compared to the consensus EPS estimate of $1.43. The company issued revenue guidance of $295.00 million-$315.00 million, compared to the consensus revenue estimate of $304.50 million.

5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ANIP stock can currently be purchased for approximately $32.14.

ANI Pharmaceuticals (NASDAQ:ANIP) has a market capitalization of $560.43 million and generates $216.14 million in revenue each year. The specialty pharmaceutical company earns $-42,600,000.00 in net income (profit) each year or ($4.30) on an earnings per share basis.

The company employs 601 workers across the globe.

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The official website for the company is www.anipharmaceuticals.com. The specialty pharmaceutical company can be reached via phone at (218) 634-3500, via email at ir@anipharmaceuticals.com, or via fax at 218-634-3540.